What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from customers using ancestry testing and other services.

Drugmaker Regeneron Pharmaceuticals says it will comply with privacy policies regarding the use of customer data. 23andMe's bankruptcy filings had drawn scrutiny from lawmakers who warned that millions of customers' genetic data could be sold to unscrupulous buyers.